{"id":"NCT00314145","sponsor":"Sanofi","briefTitle":"A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX","officialTitle":"A Multicentre, Randomized, Double-blind, Phase III Study of The Comparative Immunogenicity, Safety and Tolerability of Two Japanese Encephalitis Vaccines (ChimeriVax™-JE and JE-VAX®)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11","primaryCompletion":"2006-06","completion":"2006-11","firstPosted":"2006-04-13","resultsPosted":"2012-12-05","lastUpdate":"2012-12-06"},"enrollment":820,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"ChimeriVax™-JE","otherNames":[]},{"type":"BIOLOGICAL","name":"JE-VAX®","otherNames":[]}],"arms":[{"label":"ChimeriVax™-JE","type":"EXPERIMENTAL"},{"label":"JE-VAX®","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous virus strain after completion of vaccination course.","primaryOutcome":{"measure":"Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion Following Either ChimeriVax™-JE or JE-Vax® Vaccination","timeFrame":"Up to Day 60 post-first vaccination","effectByArm":[{"arm":"JE-VAX®","deltaMin":null,"sd":null},{"arm":"ChimeriVax™-JE","deltaMin":324,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":13},"locations":{"siteCount":10,"countries":["United States","Australia"]},"refs":{"pmids":["20934459"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":410},"commonTop":["Headache","Injection Site Pain","Fatigue","Malaise","Myalgia"]}}